

Pathophysiology and Management of Spastic Hypertonia: Current Concepts

Michael C. Munin, M.D.

Associate Professor

Department of Physical Medicine and
Rehabilitation



Definition of Spasticity

“Spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex, as one component of the upper motor neuron syndrome.”



Upper Motor Neuron Syndrome

Positive Symptoms

- Spasticity
- Clonus
- Flexor/extensor spasm
- Hyper-reflexia
- Dystonia
- Rigidity

Negative Symptoms

- Decreased dexterity
- Weakness
- Paralysis
- Fatigability
- Slowness of movement



Etiologies

- Stroke
- Traumatic brain injury
- Multiple sclerosis
- Spinal cord injury
- Cerebral palsy
- Anoxia
- Neurodegenerative disease



Treatment Goals

Improved

ROM
Gait
Orthotic fit
Transfers
Seating
Ease of hygiene


Decreased

Energy expenditure
Spasm frequency
Pain
Caregiver burden



Algorithm for Spasticity


*Adapted from Brin, 1997



Upper Limb Spasticity Patterns



Upper Limb Spasticity Patterns



Upper Limb Spasticity Patterns




Lower Limb Spasticity Patterns




Lower Limb Spasticity Patterns



Review of Normal Function and Pathophysiology of Spastic Hypertonia




Loss of Descending Inhibition




Alpha Motor Neuron Excitability

- Denervation Hypersensitivity
- Collateral Sprouting




Effects of Immobilization in Spasticity



Connective tissue deposition



Mechanisms of Impairment in Patients With Spasticity



Spastic Dystonia




From Denny-Brown, 1966:

Tonic muscle contraction of both flexors and extensors in absence of phasic stretch or voluntary effort



Spastic Dystonia (Co-contraction)



Physical and Occupational



Modalities

- Cold (Ice), Biofeedback
- Acupuncture
- Vibration
- Electrical stimulation (NMES, FES, TES)
 - Efficacy not well documented
 - Used to:
 - Stimulate a weak agonist
 - Reduce spasticity in antagonist



Positioning Splints

- Upper and lower extremity
- Passive or dynamic
- Need to brace in appropriate positions
- ROM/stretching useful but hard to maintain with increased tone



www.wemove.org



Modalities/Splinting in Spasticity

- Adjunct to pharmacological intervention, chemodenerivation
- Not significantly helpful as monotherapy



www.wemove.org

Spasticity: Pharmacological Treatment



Oral Medications

- Benzodiazepines
- Baclofen
- Dantrolene sodium
- Tizanidine
- Clonidine
- Cyproheptadine
- Gabapentin
- 4-AP



www.wemove.org

Oral Medications

Benefits

1. Easy to administer
2. Global treatment
3. Decrease in hyperreflexia
4. Reduction in painful spasms

Side Effects

1. Sedation
2. Weakness
3. Confusion
4. Nausea
5. Dizziness/orthostasis
6. Lower seizure threshold



Chemodeneration in Spasticity



Chemodeneration

- Local muscle relaxation
- Injectable therapy
- Temporary, potentially reversible, titratable
 - Botulinum toxin
 - Phenol
 - Ethyl alcohol



Alcohol/Phenol: Histologic Effects

- Denatures protein; tissue necrosis; destroys all size axons especially on nerve outer aspect
- Low cost
- Lack of antigenicity



Alcohol/Phenol: Histologic Effects

- Duration related to area of denervated segment injected and dose



- Regeneration (re-growth of axons) occurs with fibrosis after variable period of time



Alcohol/Phenol: Duration of

– Alcohol

- 6–12 months (Tardieu et al, 45%)
- 2–3 years in limited patients

– Phenol

- Range 10–850 days, average 10–11 months
- 10–11 months (Khalili et al, 2%–3%)
- 9–22 months (Petrillo et al, 5%)
- 1–36 months (Easton et al, 5%)



Common Neurolysis

- Obturator nerve
- Musculocutaneous nerve
- Motor point to Rectus Femoris
- Motor point to Hamstrings
- Motor point to Tibial nerve
- Femoral nerve



Phenol Nerve Block to Musculocutaneous Nerve



Botulinum Toxin

- Purified toxin from clostridia bacteria
- Many serotypes based on target receptor of toxin
- Approved for treatment of cervical dystonia (Dysport-Abo, Myobloc-Rima, Botox-Ona) and upper limb post stroke spasticity (Botox-Ona)




Botulinum Toxin Serotypes

Toxin	Target
Tetanus	Synaptobrevin
Botulinum Toxin A	SNAP-25
B	Synaptobrevin
C	Synaptobrevin
D	Synaptobrevin
E	SNAP-25
F	Synaptobrevin



Motor End Plate



Botulinum toxin injection



BTX-A: Mechanism of Action

- RE-ESTABLISHING
- Single nerve sprout establishes new neuromuscular junction. Muscle tone is restored and spasms return, making it necessary to repeat injections approximately every 3 to 6 months, depending on individual patient response.



Clinical Effects of Botulinum Toxins

- Injected into overactive muscles
- Focal, temporary chemodenervation
- Onset usually within 24-72 hours
- Maximum effect at approximately 4 to 6 weeks
- Clinical benefit usually >12 weeks
- Can be used with other therapies



Phenol/Botulinum Toxin Combination Therapy

- **Phenol**
 - Large, proximal muscles
 - Spares toxin dosing
- **BTX**
 - Small, distal muscles
 - Selective targeting




Nonresponse to Botulinum Toxin

- Reasons for primary and secondary non-response
 - Dose may be too low
 - Muscles injected/technique may require modification
 - May be change in pattern of muscle involvement
 - Inappropriate reconstitution or storage of toxin
 - Neutralizing antibodies may be present



Cyclic Functional Electrical Stimulation Does Not Enhance Gains in Hand Grasp Function When Used as an Adjunct to OnabotulinumtoxinA and Task



A) Motor Activity Log–Observation, (B) Motor Activity Log–Self-Report, (C) ARAT



Orthopedic Procedures: Tendon Transfers

- **Goals**

- Weaken the overactive muscle
- Modify primary function

- **Common techniques**

- Split anterior tibialis transfer (SPLATT)
- Achilles tendon lengthening
- FDL lengthening
- Pronator to supinator transfer
- Tenodesis grasp
- Flexor carpi ulnaris transfer to extensor carpi radialis brevis or longus



Intrathecal Delivery of



Advantages of ITB Therapy

- Reversible
- Global spasticity management
- Programmable
 - allows dose titration to give optimal benefit
- Effective in reducing spasticity
 - trunk and lower > upper extremities
 - cerebral and spinal origin



Potential Risks of ITB Therapy

- Drug side effects
 - Most common
 - hypotonia, somnolence, nausea/vomiting, headaches, dizziness
- System and procedural complications
 - Infection risk 1%
- Overdose or withdrawal from lack of refill



Catheter Implant

- Insert the introducer needle into the intraspinal space at the L3-L4 level
- Remove the needle stylet and confirm CSF backflow



Inserting catheter with guide wire through the introducer needle



Pump Implant

- Abdominal incision
 - make a pocket for the pump no deeper than 2.5 cm or 1 inch



Spasticity: Summary of Treatment Options

- Rehabilitation
- Oral medication
- Intrathecal baclofen
- Chemodenervation
- Orthopedic surgery
- Other neurosurgery

Multi-modal approach based on functional goals. Not all spasticity requires treatment

